Home

Terry Dagnon

CIK 1760510 · Chief Operations Officer · last filed 2023-04-21

Terry Dagnon is a Chief Operations Officer who has filed 10 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing shows the insider sold $590.2K of OTLK on Apr 21, 2023. Across all open-market trades the lifetime net is −$726.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $43.1K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$43.1K

Companies

2

Total Filings

10

Lifetime Open-Market Net

-$726.4K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OTLK Chief Operations Officer 32,653 $1.32 $43.1K -$579.7K 4 2023-04-21
Outlook Therapeutics, Inc. (OTLKW) Delisted Chief Operating Officer 1,163,058 $0.03 $34.9K -$146.7K 6 2021-12-23

Recent Filings

10 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-04-21 OTLK Sell (S) −520,000 -$590.2K EDGAR
2023-04-19 OTLK Grant (A) — $0 EDGAR
2022-06-23 OTLK Buy (P) +10,000 $10.5K EDGAR
2022-04-04 OTLK Grant (A) — $0 EDGAR
2021-12-23 Outlook Therapeutics, Inc. (OTLKW) Delisted Grant (A) — $0 EDGAR
2021-12-06 Outlook Therapeutics, Inc. (OTLKW) Delisted Buy (P) +25,201 $34.8K EDGAR
2021-12-03 Outlook Therapeutics, Inc. (OTLKW) Delisted Buy (P) +10,000 $14.2K EDGAR
2021-02-25 Outlook Therapeutics, Inc. (OTLKW) Delisted Sell (S) −15,900 -$33.2K EDGAR
2021-02-17 Outlook Therapeutics, Inc. (OTLKW) Delisted Sell (S) −63,700 -$162.4K EDGAR
2020-04-21 Outlook Therapeutics, Inc. (OTLKW) Delisted Grant (A) +1,207,457 $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.